RenovoRx

Catheter-based drug delivery for cancer reduces systemic toxicity but requires angiographic identification of tumor-feeding vessels.

The foundation of the TAMP therapy platform

The Baptist Health South Studios presents with Dr. Ripal Gandhi, Dr. Raj Narayanan and Dr. Horacio Asbun the state of pancreatic cancer for the patient and treatment options available.

The page describes advances in minimally invasive therapies, including surgery, radiation, ablation, and endovascular treatments.

RenovoRx reports the first human use of the RenovoCath catheter for targeted fluid delivery in the vascular system.

El Camino Hospital enrolls the first patient in a safety study testing the RenovoCath for localized chemotherapy in pancreatic cancer.

RenovoRx today announced that it has achieved ISO 13485:2003 certification, an internationally recognized quality standard for medical devices. BSI (the British Standards Institution) awarded the certification.

RenovoRx announces the addition of Klaus W. Hambuechen, Laurence Marton, and Una Ryan to its Board of Directors.

Margaret Tempero studies pancreatic ductal adenocarcinoma and investigational therapeutics, and has held leadership roles in ASCO.

Dr. Agah has served as RenovoRx’s Chief Medical Officer and Co-Founder since 2009, and as Chairman of the Board since 2018.

RenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for unmet medical needs.

RenovoRx's Board Member Dr. Laurence (Larry) J. Marton, MD is a leading expert with extensive experience in the fields of drug development, with a focus on treating human diseases related to cell growth including cancer.

Advancing a new approach to how cancer therapies are delivered

The RenovoCath catheter has been FDA-cleared since 2014, meaning it has been reviewed by the U.S. Food and Drug Administration and cleared for use in patients. It is not considered an experimental medical device.